Erlotinib achieved partial response in a non-small cell lung cancer patient with gefitinib-induced interstitial lung disease

Case Reports in Oncology

Volumn 4, Issue 3, 2011, Pages 464-466

  Tian, Qing ^a   Chen, Liang An ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Epidermal growth factor receptor tyrosine kinase inhibitors; Interstitial lung disease; Non small cell lung cancer

Indexed keywords

ERLOTINIB; GEFITINIB; METHYLPREDNISOLONE; PREDNISOLONE;

ADULT; ARTICLE; ARTIFICIAL VENTILATION; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; FEVER; HUMAN; INTERSTITIAL LUNG DISEASE; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; RESPIRATORY DISTRESS; TREATMENT RESPONSE;

EID: 84855317366     PISSN: None     EISSN: 16626575     Source Type: Journal    
DOI: 10.1159/000332195     Document Type: Article

References (5)

1. Ando M, Okamoto I, Yamamoto N, et al.: Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2006;24:2549-2556. (Pubitemid 46630633)
2. Suzuki M, Asahina H, Konishi J, et al.: Recurrent gefitinib-induced interstitial lung disease. Intern Med 2008;47:533-536. (Pubitemid 351663670)
3. Takamochi K, Suzuki K, Bashar AH, et al.: Readministration of gefitinib in a responder after treatment discontinuation due to gefinitib-related interstitial lung disease: a case report. J Med Case Reports 2007;17:138.
4. Fukui T, Otani S, Hataishi R, et al.: Successful rechallenge with erlotinib in a patient with EGFR-mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease. Cancer Chemother Pharmacol 2010;65:803-806.
5. Chang S-C, Chang C-Y, Chen C-Y, et al.: Successful erlotinib rechallenge after gefitinib-induced acute interstitial pneumonia. J Thorac Oncol 2010;5:1105-1106.